IDiyas

For the Inventor, By the Inventor

Oak Park, IL, United States of America

M Eileen Dolan

USPTO Granted Patents = 15

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 128(Granted Patents)


Location History:

  • Chicago, IL (US) (1992 - 1994)
  • Oak Park, IL (US) (1996 - 2002)

Company Filing History:

goldMedal7 out of 1,217 
 
The Penn State Research Foundation
 patents
silverMedal6 out of 349 
 
Arch Development Corporation
 patents
bronzeMedal5 out of 1,215 
 
The United States of America As Represented by the Department of Health
 patents
4. 3 out of 2,202 
 
The United States of America As Represented by the Secretary of
 patents
5. 2 out of 4,119 
 
Wisconsin Alumni Research Foundation
 patents
6. 1 out of 1 
 
The of the United States of America As Represented by the Department of
 patent
7. 4 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1992-2002

Loading Chart...
15 patents (USPTO):Explore Patents
1. 6436945 - Substituted O6-benzyl-8-aza-guanines (2002-08-20),
2. 6333331 - Substituted O6-benzylguanines (2001-12-25),
3. 6303604 - Pharmaceutical composition comprising 2,4-diamino-6-benzyloxy-s-triazine and inactivation of O6-alkylguanine-DNA-alkyltransferase (2001-10-16),
4. 6172070 - Substituted O6-benzyl-8-aza-guanines and 6(4)-benzyloxypyrimidines (2001-01-09),
5. 6060458 - Oligodeoxyribonucleotides comprising O.sup.6 -benzylguanine and their use (2000-05-09),
6. 5977187 - 4-substituted-1,2-naphthoquinones and their use in the inhibition of (1999-11-02),
7. 5958932 - Substitutes O.sup.6 -benzylguanines, compositions, and methods of using (1999-09-28),
8. 5916894 - Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines (1999-06-29),
9. 5883270 - 4-substituted-1, 2-naphthoquinones and their use in the inhibition of (1999-03-16),
10. 5753668 - Substituted benzyloxypyrimidines and their inactivation of O.sup.6 (1998-05-19),
11. 5691307 - O.sup.6 -substituted guanine compositions and methods for depleting O.sup.6 (1997-11-25),
12. 5525606 - Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines (1996-06-11),
13. 5358952 - O.sup.6 -substituted guanine compounds and methods for depleting O.sup.6 (1994-10-25),
14. 5352669 - O.sup.6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds (1994-10-04),
15. 5091430 - O.sup.6 -substituted guanine compounds and methods for depleting O.sup.6 (1992-02-25),

Title: M Eileen Dolan: Innovator in Pharmaceutical Chemistry

Introduction

M Eileen Dolan is a prominent inventor based in Oak Park, Illinois. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of AGT inactivating compounds. With a total of 15 patents to her name, Dolan's work has had a substantial impact on cancer research and treatment.

Latest Patents

Among her latest patents are "Substituted O6-benzyl-8-aza-guanines" and "Substituted O6-benzylguanines." These inventions provide innovative AGT inactivating compounds, which are crucial for enhancing the efficacy of certain cancer therapies. The compounds she has developed are characterized by their unique chemical structures, which play a vital role in their functionality.

Career Highlights

Dolan has worked with notable organizations such as the Penn State Research Foundation and Arch Development Corporation. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Throughout her career, Dolan has collaborated with esteemed colleagues, including Robert C Moschel and Anthony E Pegg. These partnerships have fostered a rich environment for innovation and have led to advancements in her research.

Conclusion

M Eileen Dolan's contributions to pharmaceutical chemistry and her impressive portfolio of patents highlight her as a key figure in the field. Her work continues to influence cancer research and treatment methodologies, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…